Section Arrow
HURA.NASDAQ
- TuHURA Biosciences Inc
Quotes are at least 15-min delayed:2025/07/22 16:20 EDT
After Hours
Last
 2.69
-0.05 (-1.82%)
Bid
2.61
Ask
2.74
High 2.74 
Low 2.69 
Volume 3093 
Regular Hours
Last
 2.74
+0.19 (+7.45%)
Day High 
2.76 
Prev. Close
2.55 
1-M High
2.78 
Volume 
357.93K 
Bid
2.61
Ask
2.74
Day Low
2.55 
Open
2.58 
1-M Low
2.1 
Market Cap 
118.70M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.45 
20-SMA 2.41 
50-SMA 2.86 
52-W High 9.0125 
52-W Low 1.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.96/-0.51
Enterprise Value
118.74M
Balance Sheet
Book Value Per Share
0.21
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.053+0.002+3.92%-- 
After Hours 0.0532 +0.0002 +0.38%
PLRZPolyrizon Ltd1.45+0.5422+59.73%-- 
After Hours 1.71 +0.26 +17.93%
REPLReplimune Group2.805-9.52-77.24%-- 
After Hours 2.8 -0.005 -0.18%
IOVAIovance Biotherapeutics3.13+0.64+25.70%-- 
After Hours 3.1402 +0.0102 +0.33%
TNFATNF Pharmaceuticals Inc.0.107-0.0224-17.31%-- 
After Hours 0.106 -0.001 -0.93%
Quotes are at least 15-min delayed:2025/07/22 16:20 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.